Abstract:Key points Ranolazine, an anti‐anginal compound, improves glycaemic control in clinical trials and increases myocardial perfusion via a direct vasodilatatory effect on coronary arteries. Skeletal muscle microvasculature controls the delivery of nutrient and hormones into muscle and their exchanges between plasma and muscle interstitium by providing microvascular exchange surface area. In this study we examined whether ranolazine improves glycaemic control via exerting vasodilatatory action on the pre‐capillary arterioles to recruit muscle microvasculature. We demonstrate that ranolazine potently recruits muscle microvasculature, which expands microvascular endothelial surface area in muscle and results in increased muscle delivery and action of insulin. The results help us better understand the physiological mechanism by which ranolazine improves glycaemic control and its potential as an insulin‐sensitizing agent. Abstract Ranolazine, an anti‐anginal compound, has been shown to significantly improve glycaemic control in large‐scale clinical trials, and short‐term ranolazine treatment is associated with an improvement in myocardial blood flow. As microvascular perfusion plays critical roles in insulin delivery and action, we aimed to determine if ranolazine could improve muscle microvascular blood flow, thereby increasing muscle insulin delivery and glucose use. Overnight‐fasted, anaesthetized Sprague‐Dawley rats were used to determine the effects of ranolazine on microvascular recruitment using contrast‐enhanced ultrasound, insulin action with euglycaemic hyperinsulinaemic clamp, and muscle insulin uptake using 125I‐insulin. Ranolazine's effects on endothelial nitric oxide synthase (eNOS) phosphorylation, cAMP generation and endothelial insulin uptake were determined in cultured endothelial cells. Ranolazine‐induced myographical changes in tension were determined in isolated distal saphenous artery. Ranolazine at therapeutically effective dose significantly recruited muscle microvasculature by increasing muscle microvascular blood volume (∼2‐fold, P < 0.05) and increased insulin‐mediated whole body glucose disposal (∼30%, P= 0.02). These were associated with an increased insulin delivery into the muscle (P < 0.04). In cultured endothelial cells, ranolazine increased eNOS phosphorylation and cAMP production without affecting endothelial insulin uptake. In ex vivo studies, ranolazine exerted a potent vasodilatatory effect on phenylephrine pre‐constricted arterial rings, which was partially abolished by endothelium denudement. In conclusion, ranolazine treatment vasodilatates pre‐capillary arterioles and increases microvascular perfusion, which are partially mediated by endothelium, leading to expanded microvascular endothelial surface area available for nutrient and hormone exchanges and resulting in increased muscle delivery and action of insulin. Whether these actions contribute to improved glycaemic control in patients with insulin resistance warrants further investigation.

Angiotensin-(1-7) Recruits Muscle Microvasculature and Enhances Insulin's Metabolic Action Via Mas Receptor.

Abstract 160: Angiotensin-(1-7) Decreases the Pro-inflammatory Effects of Prorenin in Hypothalamic Microglia

Direct Activation of Angiotensin II Type 2 Receptors Enhances Muscle Microvascular Perfusion, Oxygenation, and Insulin Delivery in Male Rats

Ang-(1-7) Improves Islet B Cell Function By Up-Regulating The Activity Of Ang-(1-7)-Mas Axis/Pdx-1

Losartan Increases Muscle Insulin Delivery and Rescues Insulin'S Metabolic Action During Lipid Infusion Via Microvascular Recruitment

Mas receptor mediates cardioprotection of angiotensin-(1-7) against Angiotensin II-induced cardiomyocyte autophagy and cardiac remodelling through inhibition of oxidative stress.

Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas

Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment.

Angiotensin(1-7) activates MAS-1 and upregulates CFTR to promote insulin secretion in pancreatic beta-cells: the association with type 2 diabetes

Angiotensin(1|[ndash]|7) attenuates the progression of streptozotocin-induced diabetic renal injury better than angiotensin receptor blockade

Ranolazine Recruits Muscle Microvasculature and Enhances Insulin Action in Rats.

Globular Adiponectin Enhances Muscle Insulin Action Via Microvascular Recruitment and Increased Insulin Delivery

Angiotensin(1-7) attenuates visceral adipose tissue expansion and lipogenesis by suppression of endoplasmic reticulum stress via Mas receptor

Central angiotensin 1-7 triggers brown fat thermogenesis

The angiotensin-converting enzyme 2/angiotensin (1-7)/Mas axis protects the function of pancreatic β cells by improving the function of islet microvascular endothelial cells

Angiotensin-(1-7) and its Mas receptor i an advance

Counteraction Between Angiotensin II and Angiotensin-(1–7) Via Activating Angiotensin Type I and Mas Receptor on Rat Renal Mesangial Cells

Glucagon-Like Peptide 1 Recruits Microvasculature And Increases Glucose Use In Muscle Via A Nitric Oxide-Dependent Mechanism

Angiotensin-(1–7) Modulates Angiotensin II-Induced Vasoconstriction in Human Mammary Artery

Angiotensin-(1-7): beyond the cardio-renal actions

Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor